Impel NeuroPharma (IMPL) IPO Opens 2% Higher

Today's IPO for Impel NeuroPharma, Inc. (NASDAQ: IMPL) opened for trading at $15.31 after pricing 5,333,334 shares of its common stock at a price to the public of $15.00 per share.

Cowen and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow is acting as lead manager.

Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

You May Also Be Interested In